Arash Delavar1,2, Justin M Barnes3, Xiaoyan Wang2, Kimberly J Johnson2,4. 1. Medical Student, University of California, San Diego, School of Medicine, La Jolla. 2. Brown School Master of Public Health Program, Washington University in St Louis, St Louis, Missouri. 3. Medical Student, St Louis University School of Medicine, St Louis, Missouri. 4. Siteman Cancer Center, Washington University in St Louis, St Louis, Missouri.
Abstract
Importance: Although US cancer survival rates have increased over time, disparities by race/ethnicity remain, including for children and adolescents. Objective: To examine whether racial/ethnic disparities in childhood and adolescent cancer survival vary by cancer type according to relative survival rates (RSRs), a marker for amenability to medical intervention. Design, Setting, and Participants: In a retrospective cohort study using US Surveillance, Epidemiology, and End Results data, 67 061 children and adolescents diagnosed at ages 0 to 19 years with a first primary malignant cancer from January 1, 2000, to December 31, 2016, were evaluated. Data analysis was performed from June 19 to November 3, 2019. Participants were followed up from the dates of diagnosis to cancer death or the end of the follow-up period, whichever came first. Exposures: Race/ethnicity defined as non-Hispanic white, non-Hispanic black, non-Hispanic American Indian/Alaskan Native, non-Hispanic Asian or Pacific Islander, or Hispanic (any race). Main Outcomes and Measures: Cancer amenability was defined using 5-year RSRs for 103 cancer types. Cox proportional hazards regression was used to compute adjusted hazard ratios (aHRs) and 95% CIs for the association between race/ethnicity and cancer survival for high (>85% RSR), medium (70%-85% RSR), and low (<70% RSR) amenability categories. Results: Among 67 061 cancer cases, 36 064 were male (53.8%); most individuals were non-Hispanic white (35 186 [52.5%]) followed by Hispanic of any race (19 220 [28.7%]), non-Hispanic black (7100 [10.6%]), non-Hispanic Asian or Pacific Islander (4981 [7.4%]), and non-Hispanic American Indian/Alaskan Native (574 [0.9%]). Mean (SD) age at diagnosis was 9.66 (6.41) years. Compared with non-Hispanic white children and adolescents, a higher aHR of death was observed for high- than low-amenability cancers for non-Hispanic black patients (high: aHR, 1.59; 95% CI, 1.41-1.80 vs low: aHR, 1.35; 95% CI, 1.24-1.47; P = .002 for interaction) and Hispanic (any race) patients (high: aHR, 1.63; 95% CI, 1.50-1.78 vs low: aHR, 1.16; 95% CI, 1.08-1.25; P < .001 for interaction). Results for other race/ethnicities showed similar patterns but were not statistically significant. Conclusions and Relevance: Racial/ethnic minority children and adolescents were observed to have a higher risk of death than non-Hispanic white children and adolescents, with more amenable cancers having larger relative survival differences. This disparity may be associated with a combination of factors, including differences in access to health care resources.
Importance: Although US cancer survival rates have increased over time, disparities by race/ethnicity remain, including for children and adolescents. Objective: To examine whether racial/ethnic disparities in childhood and adolescent cancer survival vary by cancer type according to relative survival rates (RSRs), a marker for amenability to medical intervention. Design, Setting, and Participants: In a retrospective cohort study using US Surveillance, Epidemiology, and End Results data, 67 061 children and adolescents diagnosed at ages 0 to 19 years with a first primary malignant cancer from January 1, 2000, to December 31, 2016, were evaluated. Data analysis was performed from June 19 to November 3, 2019. Participants were followed up from the dates of diagnosis to cancer death or the end of the follow-up period, whichever came first. Exposures: Race/ethnicity defined as non-Hispanic white, non-Hispanic black, non-Hispanic American Indian/Alaskan Native, non-Hispanic Asian or Pacific Islander, or Hispanic (any race). Main Outcomes and Measures: Cancer amenability was defined using 5-year RSRs for 103 cancer types. Cox proportional hazards regression was used to compute adjusted hazard ratios (aHRs) and 95% CIs for the association between race/ethnicity and cancer survival for high (>85% RSR), medium (70%-85% RSR), and low (<70% RSR) amenability categories. Results: Among 67 061 cancer cases, 36 064 were male (53.8%); most individuals were non-Hispanic white (35 186 [52.5%]) followed by Hispanic of any race (19 220 [28.7%]), non-Hispanic black (7100 [10.6%]), non-Hispanic Asian or Pacific Islander (4981 [7.4%]), and non-Hispanic American Indian/Alaskan Native (574 [0.9%]). Mean (SD) age at diagnosis was 9.66 (6.41) years. Compared with non-Hispanic white children and adolescents, a higher aHR of death was observed for high- than low-amenability cancers for non-Hispanic black patients (high: aHR, 1.59; 95% CI, 1.41-1.80 vs low: aHR, 1.35; 95% CI, 1.24-1.47; P = .002 for interaction) and Hispanic (any race) patients (high: aHR, 1.63; 95% CI, 1.50-1.78 vs low: aHR, 1.16; 95% CI, 1.08-1.25; P < .001 for interaction). Results for other race/ethnicities showed similar patterns but were not statistically significant. Conclusions and Relevance: Racial/ethnic minority children and adolescents were observed to have a higher risk of death than non-Hispanic white children and adolescents, with more amenable cancers having larger relative survival differences. This disparity may be associated with a combination of factors, including differences in access to health care resources.
Authors: John Cologne; Wan-Ling Hsu; Robert D Abbott; Waka Ohishi; Eric J Grant; Saeko Fujiwara; Harry M Cullings Journal: Epidemiology Date: 2012-07 Impact factor: 4.822
Authors: Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2014-01-31 Impact factor: 508.702
Authors: Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-06-02 Impact factor: 508.702
Authors: Joshua P Muñiz; John P Woodhouse; Amy E Hughes; Sandi L Pruitt; Karen R Rabin; Michael E Scheurer; Philip J Lupo; Jeremy M Schraw Journal: Pediatr Hematol Oncol Date: 2022-03-09 Impact factor: 2.070
Authors: Bryan A Sisk; Megan Keenan; Melody S Goodman; Argentina E Servin; Lauren H Yaeger; Jennifer W Mack; James M DuBois Journal: Patient Educ Couns Date: 2021-12-30
Authors: Satomi Sato; Nan Li; Stephanie B Dixon; Miho Kato; Hui Zhang; Chi Kong Li; Rebecca M Howell; Wendy M Leisenring; Smita Bhatia; Kevin C Oeffinger; Gregory T Armstrong; Yutaka Yasui; Kevin R Krull; Yin Ting Cheung Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-04 Impact factor: 4.254
Authors: Jessica D Thompkins; Jennifer Needle; Justin N Baker; Linda Briggs; Yao I Cheng; Jichuan Wang; Sarah Friebert; Maureen E Lyon Journal: Pediatrics Date: 2021-05-06 Impact factor: 9.703
Authors: Maureen E Lyon; Yao I Cheng; Jennifer Needle; Sarah Friebert; Justin N Baker; Jiji Jiang; Jichuan Wang Journal: Pediatr Blood Cancer Date: 2021-06-01 Impact factor: 3.167